Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.

[1]  S. Oparil,et al.  Long‐term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease , 2018, Journal of clinical hypertension.

[2]  G. Bakris,et al.  Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension , 2017, Journal of clinical hypertension.

[3]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[4]  W. Cushman,et al.  Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension , 2012, Hypertension.

[5]  G. Reboldi,et al.  Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin–angiotensin system blockers , 2012, Therapeutic advances in cardiovascular disease.

[6]  A. Weder,et al.  Chlorthalidone Reduces Cardiovascular Events Compared With Hydrochlorothiazide: A Retrospective Cohort Analysis , 2011, Hypertension.

[7]  G. Bakris,et al.  Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension , 2011, Hypertension.

[8]  G. Bakris,et al.  The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure , 2011, Journal of clinical hypertension.

[9]  S. Nesbitt,et al.  Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. , 2010, Hypertension.

[10]  L. Wolfson,et al.  Long-Term Reproducibility of Ambulatory Blood Pressure is Superior to Office Blood Pressure in the Very Elderly , 2010, Journal of Human Hypertension.

[11]  H. Dastani,et al.  Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy. , 2008, P & T : a peer-reviewed journal for formulary management.

[12]  G. Bergus,et al.  Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure , 2006, Hypertension.

[13]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[14]  W. White,et al.  Long‐term reproducibility of ambulatory blood pressure , 1994, Journal of hypertension.

[15]  H. M. A. Abraham,et al.  The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases , 2014, Drug Safety.

[16]  P. Levy,et al.  Therapy of Hypertension in African Americans , 2011, American Journal of Cardiovascular Drugs.

[17]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.